221 SYNERGY-1: A Phase 1, first-in-human, randomized, double-blind, placebo-controlled safety, tolerability, immunogenicity, PK and PD study of KP104 in escalating single and multiple doses

221 SYNERGY-1: A Phase 1, first-in-human, randomized, double-blind, placebo-controlled safety, tolerability, immunogenicity, PK and PD study of KP104 in escalating single and multiple doses

Saved in:
Bibliographic Details
Published in:Immunobiology (1979) Vol. 228; no. 5; p. 152671
Main Authors: Wabinitz, Paul, Ma, Jay, Tsui, Ping, Fu, Helen, He, Chaomei, Wu, Jingtao, Yu Christina Weng, Qing, Rankin, Jon, Song, Wenru, Farinola, Nicholas, Lee, Richard
Format: Journal Article
Language:English
Published: Elsevier GmbH 01-09-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0171-2985
1878-3279
DOI:10.1016/j.imbio.2023.152671